SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Candel Therapeutics reports phase 3 prostate cancer biomarker data

The company said the data from its completed aglatimagene besadenovec trial showed sustained immune remodeling more than two years after treatment versus radiotherapy alone.

CADL.O

Related stories